Our data demonstrate for the first time that the endocytosis inhibitor PCZ can inhibit the internalization of EGFR in CRC cells and help it aggregate on cell membranes, which enhances cetuximab‐mediated ADCC activity. The gene discussed is EGFR; the disease is colorectal carcinoma.